Lacosamide

Nat Rev Drug Discov. 2008 Dec;7(12):973-4. doi: 10.1038/nrd2764.

Abstract

In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.

MeSH terms

  • Acetamides / therapeutic use*
  • Adult
  • Analgesics / therapeutic use
  • Animals
  • Anticonvulsants / therapeutic use*
  • Disease Models, Animal
  • Epilepsies, Partial / drug therapy*
  • Epilepsy, Temporal Lobe / drug therapy*
  • Humans
  • Lacosamide
  • Randomized Controlled Trials as Topic
  • Rats

Substances

  • Acetamides
  • Analgesics
  • Anticonvulsants
  • Lacosamide